How Does Spravato Work? Mechanism of Action Explained in Plain English

Most antidepressants you've heard of — SSRIs like Prozac or Zoloft, SNRIs like Effexor — work by affecting serotonin, dopamine, or norepinephrine. Spravato (esketamine) works through a completely different mechanism, targeting a separate brain pathway called the glutamate system. This difference is why Spravato can produce antidepressant effects within hours rather than weeks.

Here's a plain-English explanation of how Spravato actually works in the brain.

The Problem With Traditional Antidepressants

For decades, the dominant theory of depression was that it resulted from low levels of neurotransmitters like serotonin, norepinephrine, and dopamine — the "chemical imbalance" model. SSRIs and SNRIs were developed to correct these imbalances by keeping these neurotransmitters active in the spaces between neurons for longer.

The problem? These medications take weeks to work, and for about 30% of people with major depression (those with treatment-resistant depression, or TRD), they don't produce adequate relief at all — even after trying multiple different options.

What Is the Glutamate System?

Glutamate is the most abundant excitatory neurotransmitter in the brain. While serotonin and dopamine get most of the attention, glutamate is involved in an enormous proportion of all brain communication — including in the regions that regulate mood, memory, learning, and emotional processing.

In depression, researchers have observed disruptions in glutamate signaling in key mood-regulating areas of the brain, particularly the prefrontal cortex and hippocampus. These disruptions are associated with reduced synaptic connections — fewer communication pathways between neurons — which contributes to the functional impairments seen in severe depression.

How Spravato Blocks the NMDA Receptor

Spravato (esketamine) is a non-competitive NMDA (N-methyl-D-aspartate) receptor antagonist. Here's what that means in plain English:

NMDA receptors are channels on the surface of brain cells that glutamate activates to pass signals between neurons.

"Antagonist" means blocker — esketamine blocks these NMDA receptors, preventing glutamate from activating them in the usual way.

"Non-competitive" means esketamine doesn't compete with glutamate for the same binding site — it enters the NMDA receptor channel while it's open and physically blocks it from the inside.

What Happens When NMDA Receptors Are Blocked?

When esketamine blocks NMDA receptors, it triggers a cascade of downstream effects in the brain. The current scientific understanding (though the exact mechanism is still being studied) is:

NMDA receptor blockade leads to increased release of glutamate in certain brain circuits.

This triggers activation of a different glutamate receptor type — the AMPA receptor — which sets off signaling cascades inside neurons.

These cascades stimulate production of BDNF (Brain-Derived Neurotrophic Factor) — sometimes called "brain fertilizer" — a protein that promotes the growth and connection of neurons.

Synaptogenesis — the formation of new synapses (connections between neurons) — occurs rapidly, restoring communication pathways that were weakened by depression.

This rapid synaptogenesis is believed to be the reason Spravato produces antidepressant effects within hours rather than weeks — neural reconnection happens quickly, and with it, mood and function can improve.

Why Does Spravato Cause Dissociation?

The same NMDA receptor blockade that produces antidepressant effects is also responsible for the dissociative side effects — the feeling of detachment, floating, or being "spaced out" that many patients experience during a session. NMDA receptors play a role in sensory processing and consciousness, and blocking them temporarily disrupts the normal integration of sensory experience.

This dissociation is why Spravato requires 2+ hours of post-dose clinical monitoring and why patients cannot drive until the following day.

How Is Spravato Different From Other NMDA Antagonists?

Spravato is not the only NMDA antagonist used in medicine:

Racemic IV ketamine: Works through the same NMDA pathway; used off-label for depression; not FDA-approved for depression; usually self-pay

Auvelity (dextromethorphan/bupropion): Oral NMDA antagonist component; FDA-approved for MDD; taken at home; less potent NMDA blockade than esketamine

Memantine (Namenda): NMDA antagonist approved for Alzheimer's disease; studied but not approved for depression

What makes esketamine unique is that it is the S-enantiomer of ketamine — believed to be more potent at NMDA blockade and to have better pharmacokinetics than the R-enantiomer. Its intranasal delivery also makes it more predictable in dosing than IV ketamine infusions administered at varying concentrations.

An Important Note: The Mechanism Is Still Being Studied

It's worth noting that while the NMDA receptor antagonism and downstream glutamate effects are well-established, the FDA's official label for Spravato states that "the mechanism by which esketamine exerts its antidepressant effect is unknown." The glutamate/synaptogenesis model is the leading scientific hypothesis but is still actively being investigated. Neuroscience of depression and of esketamine specifically remains an active area of research.

medfinder: Supporting Your Complete Medication Regimen

Understanding how Spravato works is one piece of managing TRD. Another piece is ensuring all the other medications in your regimen are consistently available. medfinder calls local pharmacies to find which ones have your prescriptions in stock — saving you time and stress so you can focus on your mental health.

Also read: Spravato Side Effects: What to Expect and When to Call Your Doctor.